Novo Nordisk A/S
NOVO-B
Rangering i aksjer
#107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Aksjekurs
$39.74
Markedsverdi
$175.38B
Endring (1 dag)
1.28%
Endring (1 år)
-25.58%
Land
DK
Handel Novo Nordisk A/S (NOVO-B)
Kategori
Healthcare
Inntekter for Novo Nordisk A/S (NOVO-B)
Inntekter i Dec 2025 TTM: $20.51B
Ifølge Novo Nordisk A/S sine nyeste økonomiske rapporter er selskapets nåværende resultat $20.51B. I 2024 hadde selskapet et resultat på $17.75B, en økning sammenlignet med resultatet i 2023, som var $15.50B. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Novo Nordisk A/S fra 2001 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $20.51B | 0.00% |
| 2025 | $20.51B | 15.55% |
| 2024 | $17.75B | 14.50% |
| 2023 | $15.50B | 55.92% |
| 2022 | $9.94B | 10.02% |
| 2021 | $9.03B | 3.59% |
| 2020 | $8.72B | 19.69% |
| 2019 | $7.29B | -0.35% |
| 2018 | $7.31B | -6.79% |
| 2017 | $7.84B | 15.64% |
| 2016 | $6.78B | 7.06% |
| 2015 | $6.34B | 14.26% |
| 2014 | $5.55B | -7.59% |
| 2013 | $6.00B | 22.00% |
| 2012 | $4.92B | 28.80% |
| 2011 | $3.82B | 16.43% |
| 2010 | $3.28B | 21.42% |
| 2009 | $2.70B | 13.54% |
| 2008 | $2.38B | 10.14% |
| 2007 | $2.16B | 33.54% |
| 2006 | $1.62B | 24.30% |
| 2005 | $1.30B | -5.19% |
| 2004 | $1.37B | 6.85% |
| 2003 | $1.28B | 44.62% |
| 2002 | $888.11M | 23.73% |
| 2001 | $717.79M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $33.60B | 63.84% |
US
|
|
| $17.74B | -13.50% |
US
|
|
| $8.70B | -57.58% |
US
|
|
| $5.95B | -70.99% |
US
|
|
| $21.39B | 4.31% |
CH
|
